Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Cyndescope Inc. is a technology company focusing on software solutions for the hea...
Cyndescope Inc. is a technology company focusin...
Dynatronics is a leading medical device company committed to providing high-qualit...
Dynatronics is a leading medical device company...
The ONLY patented, drug free, saline free, all natural, DAILY nasal hygiene wash, ...
The ONLY patented, drug free, saline free, all ...
DURECT is a biopharmaceutical company actively developing therapeutics based on it...
DURECT is a biopharmaceutical company actively ...
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developi...
Eloxx Pharmaceuticals, Inc. is a clinical-stage...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
Join the National Investor Network and get the latest information with your interests in mind.